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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease of unknown etiology with chronic joint inflammation.
The major autoantibody detected in RA patients is rheuma-
toid factor (RF). RF positivity is included in the American
College of Rheumatology (ACR) (1) classification criteria for
the diagnosis of RA. RF assay is an easy, convenient method
using automatic instruments. However, since RF is detect-
ed in only 50-80% of RA sera (2) and frequently present in
patients with other autoimmune disease and in the elderly
healthy population (3), diagnosis of RA using RF assay remains
suboptimal. Other autoantibodies detected in RA are anti-
RA33, anti-Sa, anti-p68, anti-calpastatin, and antiperinu-
clear factor (2), but these antoantibodies have demonstrated
lower sensitivity for the diagnosis of RA.
Among autoantibodies found in RA, the antiperinuclear
factor (APF) that recognizes perinuclear granules in human
buccal keratinocytes (4), and the antikeratin antibody (AKA)
that recognizes water-soluble acidic-neutral isoforms of filag-
grin in the human epidermis (5) and various molecular forms
of (pro) filaggrin in the rat esophagus epithelium (6), were
known to be the most specific antibodies in RA. APF and
AKA, which had been considered as different antibodies at
first, were recognized to belong to the same autoantibody
family directed to (pro) filaggrin, so both of them are called
antifilaggrin autoantibodies at present (7, 8). Vincent et al.
reported that the sensitivity of APF was 67% and a specificity
was 93%, and AKA showed a sensitivity of 52% and a speci-
ficity was 97% (9) in RA patients. However, performance of
APF assay was restricted to a few specialized laboratories
because the technique was subjective and laborious, because
of the necessity to use preselected buccal cell donors, and the
problematic interlaboratory standardization (2).
Recently, Schellekens et al. discovered that antibodies spe-
cific for RA containing citrulline residues were the same as
those defined as APF and AKA, and were detected in over
80% of RA sera using several synthetic peptides (10). These
citrullinated peptides are formed by post-translational modi-
fication of arginine residues to citrulline residues by the enzyme
peptidyl-arginine deiminase (11). The antibodies to these cit-
rullinated peptides such as anti-cyclic citrullinated peptides
antibodies (anti-CCP) and anti-filaggrin antibodies (AFA) have
been reported to be highly specific for RA (2, 12). These new
serological tests have advantage of easy performance by con-
venient enzyme linked immunosorbent assay (ELISA) method.
We studied the diagnostic performances of anti-CCP and
AFA by ELISA method and compared those with the diag-
nostic performance of RF. We also evaluated whether anti-
CCP and AFA were useful serological tools to diagnose RA
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Diagnostic Performances of Anti-Cyclic Citrullinated Peptides Antibody
and Antifilaggrin Antibody in Korean Patients with Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease of unknown etiology.
We studied the diagnostic performances of anti-cyclic citrullinated peptides antibody
(anti-CCP) assay and recombinant anti-citrullinated filaggrin antibody (AFA) assay
by enzyme linked immunosorbent assay (ELISA) in patients with RA in Korea. Diag-
nostic performances of the anti-CCP assay and AFA assay were compared with that
of rheumatoid factor (RF) latex fixation test. RF, anti-CCP, and AFA assays were
performed in 324 RA patients, 251 control patients, and 286 healthy subjects. The
optimal cut off values of each assay were determined at the maximal point of area
under the curve by receiver-operator characteristics (ROC) curve. Sensitivity (72.8%)
and specificity (92.0%) of anti-CCP were better than those of AFA (70.3%, 70.5%),
respectively. The diagnostic performance of RF showed a sensitivity of 80.6% and
a specificity of 78.5%. Anti-CCP and AFA showed positivity in 23.8% and 17.3% of
seronegative RA patients, respectively. In conclusion, we consider that anti-CCP
could be very useful serological assay for the diagnosis of RA, because anti-CCP
revealed higher diagnostic specificity than RF and AFA at the optimal cut off values
and could be performed by easy, convenient ELISA method.
Key Words : Arthritis, Rheumatoid; Rheumatoid Factor; Anti-cyclic citrullinated peptide; Anti-citrullinated filag-
grin Antibody
Received : 6 October 2004




Serum samples were obtained from 324 patients diagnosed
as RA according to the ACR criteria (1), and from 251 out-
patients with other rheumatic disease from the department of
Rheumatology. 286 healthy subjects were considered as con-
trol group and all the samples were screened by comprehen-
sive Medical testing from the Department of Family Medicine
at Eulji University Hospital from January to May, 2002. The
serum samples were aliquoted and stored at -70℃ until as-
sayed. Patient’s charts were reviewed for demographic infor-
mation, clinical diagnoses, and other laboratory data. Sex
ratio was 49 males (15.1%) and 275 females (84.9%) in RA
patients and 41 males (16.3%) and 210 females (83.7%) in
other rheumatic diseases. RA patients showed 14.6 (2-41)
years in disease duration and had been treated with various
disease modifying antirheumatic drug (DMARD). Other
rheumatic diseases included osteoarthritis (n=142), fibromyalgia
(n=24), systemic lupus erythematosus (SLE) (n=20), Behcet’s
disease (n=16), juvenile RA (n=15), gout (n=12), spondy-
loarthritis (n=7), ankylosing spondyloarthritis (n=6), systemic
sclerosis (n=3), reactive arthritis (n=3), carpal tunnel syndrome
(n=1), mixed connective tissue disease (n=1), and myofascial
syndrome (n=1) (Table 1).
Methods
Anti-CCP assay was determined by using highly purified
synthetic cyclic citrullinated peptides as substrates. AFA assay
was performed using the recombinant human filaggrin con-
taining citrulline residues after in vitro deimination. Either
anti-CCP or AFA was determined by the ELISA method
(Tohso, Tokyo, Japan) according to the manuals. RF was mea-
sured by the latex fixation test by Hitachi 7170 (Hitachi
Co, Tokyo, Japan). We used DIASTAT anti-CCP kit (MBL
Co., Nagoya, Japan) for the measurement of anti-CCP, and
anti-citrullinated filaggrin ELISA kit (MBL Co., Nagoya,
Japan) for AFA. Control sera were included on all plates to
monitor plate to plate variation. Variation never exceeded
5% and values were not corrected. The optimal cut off values
of each tests were determined at the maximal point of area Number
Rheumatoid arthritis  324
Disease controls  251
Ankylosing spondylitis  6
Behcet’s disease 16
Carpal tunnel syndrome  1
Fibromyalgia 24
Gout 12
Juvenile rheumatoid arthritis  15
Mixed connective tissue disease 1
Myofascial pain syndrome  1
Osteoarthritis 142
Reactive arthritis  3
Spondyloarthritis 7
Systemic lupus erythematosus  20
Systemic sclerosis 3
Healthy controls 286








RA 324 59.1±125.6 3-247 48.9±86.6 0.2-133.4 28.4±100.0 0.6-300.0
Male 49 95.7±163.6 3-214 47.2±85.2 0.4-100.0 27.0±79.4 0.6-169.3
Female 275 52.6±113.2 3-247 49.2±87 0.2-133.4 28.6±103.4 0.8-300.0
Non-RA 251 11.3±38.6 2-188 4.5±35.2 0.1-100.0 5.8±19.8 0.7-104.5
Male 41 8.3±22.3 2-71 5.8±43.2 0.2-100.0 6.3±32.2 0.7-104.5
Female 210 11.9±41.0 2-188 4.2±33.4 0.-100.0 5.7±16.5 0.7-84.2
Healthy controls 286 6.1±6.6 1-19 0.8±1.4 0.2-5.2 4.9±11.6 1.0-47.0
Male 132 6.3±7.4 1-19 0.8±1.4 0.2-5.2 5.5±14.0 1.2-47.0
Female 154 6.0±5.8 1-17 0.7±1.2 0.2-3.9 4.5±8.8 1.0-40.5
Table 2. Comparison of RF, anti-CCP and AFA among the patients with RA, non-RA, and healthy controls
RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide antibodies; AFA, anti-filaggrin antibodies; RA, rheumatoid arthritis; SD, standard deviation.
*Diseases of anti-CCP (+): Behcet's disease (n=1), fibromyalgia (n=1), 
gout (n=2), juvenile rheumatoid arthritis (n=6), osteoarthritis (n=6), reac-
tive arthritis (n=1), spondyloarthritis (n=2), and systemic lupus erythe-
matosus (n=1).
No. (%) of RA 
patients (n=324) 
No. (%) of non-RA
patients (n=251)
Anti-CCP (+) 236 (72.8) 20 (8.0)*
RF (+) 221 (68.2) 12 (4.8)
RF (-) 15 (4.6) 8 (3.2)
Anti-CCP (-) 88 (27.2) 231 (92.0)
RF (+) 40 (12.4) 42 (16.7)
RF (-) 48 (14.8) 189 (75.3)
Table 3. Test results at the optimal cut off value for anti-CCP and
RF in patients with and without RAunder the curve by receiver-operator characteristics (ROC)
curve and we determined and compared the diagnostic per-
formances among anti-CCP, AFA, and RF. 
Statistics
These results were analyzed by SPSS (version 10.0) and
MedCalc software (Mariakerke, Belgium). Comparisons of
data between groups were made by chi-square test and Mann
Whitney U test.
P-value less than 0.05 was regarded as significant. 
RESULTS
Titer distribution of anti-CCP, AFA, and RF tests in healthy
subjects
Total number of healthy subjects was 286 (132 male, 154
female) with a mean age of 50.4 yr (16-72 yr). The range of
anti-CCP, AFA, and RF was 0.2-5.2 U/mL, 1.0-47.0 U/mL,
and 1-19 U/mL, respectively. All tests showed no significant
differences in the mean value between male and female (Table
2). The positive numbers of anti-CCP, AFA, and RF were 3
(1.3%), 73 (25.5%), and 42 (14.7%) at the optimal cut off
values, respectively. The cut off value of anti-CCP, AFA, and
RF was 3.8 U/mL, 4.5 U/mL, and 9 U/mL, respectively.
Healthy subjects with anti-CCP positivity did not have any
other rheumatic disease.
Titer distribution of anti-CCP, AFA, and RF tests in RA
patients and disease control group
The male:female ratio was 1:5.6 with a mean age of 51 yr
(22-83 yr) in RA patients. The range of anti-CCP titers in RA
was 0.2-133.4 U/mL and showed no significant difference in
the mean value between male and female (p=0.761) (Table 2).
The range of AFA titers was 0.6-300 U/mL and showed no
significant difference in the mean value between male and
female (p=0.832). The male:female ratio was 1:5.1 with a
mean age of 53.4 yr (4-90 yr) in disease control group. The
range of anti-CCP and AFA titers were 0.1-100.0 U/mL and
0.7-104.5 U/mL in the patients with other rheumatic disease,
respectively. The range of RF titers was 3-247 U/mL and
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*Diseases of AFA (+): Behcet’s disease(n=1), fibromyalgia (n=3), gout
(n=1), juvenile rheumatoid arthritis (n=4), osteoarthritis (n=10), spondy-
loarthritis (n=1), systemic lupus erythematosus (n=1), and systemic scle-
rosis (n=1).
No. (%) of RA 
patients (n=324) 
No. (%) of non-RA
patients (n=251)
AFA (+) 145 (44.8) 27 (10.8)*
RF (+) 131 (40.4) 13 (5.2)
RF (-) 14 (4.4) 14 (5.4)
AFA (-) 179 (55.2) 224 (89.2)
RF (+) 112 (34.6) 29 (11.6)
RF (-) 67 (20.6) 195 (77.6)
Table 4. Test results at the optimal cut off value for AFA and RF







Anti-CCP 72.8 92.0 3.8
AFA 70.3 69.3 4.5
RF 80.6 78.5 9
Table 5. Diagnostic sensitivities and specificities for anti-CCP,
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Fig. 1. Receiver operator characteristics (ROC) curves of anti-CCP
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Fig. 2. Receiver operator characteristics (ROC) curves of AFA and
RF with or without RA (p=0.000).
Antifilaggrin antibody (Area=0.750)
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revealed a significant difference between male (95.7 U/mL)
and female (52.6 U/mL) in the mean value in RA (p=0.001).
The range of RF titers was 2-188 U/mL in the patients with
other rheumatic disease. Our results showed significant dif-
ference in the anti-CCP, AFA, RF titer between RA patients
and disease control group (p=0.000).
Diagnostic performances 
The cut off value of anti-CCP, AFA, and RF was 3.8 U/mL,
4.5 U/mL, 9 U/mL (Table 5). Anti-CCP showed 72.8% of
sensitivity and 92% of specificity (Table 3, 5). The false posi-
tivity of anti-CCP assay in RA was 8.0% and following dis-
eases were included; Behcet’s disease (n=1), fibromyalgia (n=1),
gout (n=2), juvenile rheumatoid arthritis (n=6), osteoarthritis
(n=6), reactive arthritis (n=1), spondyloarthritis (n=2), and
SLE (n=1) (Table 3). Anti-CCP positivity was 23.8% among
sero-negative RA patients. AFA showed 70.3% of sensitivity
and 69.3% of specificity (Table 4, 5). The false positivity of
AFA in RA was 10.8% and following diseases were included;
Behcet’s disease (n=1), fibromyalgia (n=3), gout (n=1), juve-
nile rheumatoid arthritis (n=4), osteoarthritis (n=10), spondy-
loarthritis (n=1), SLE (n=6), and systemic sclerosis (n=1)
(Table 4). AFA positivity was 17.3% among seronegative RA
patients. RF showed 80.6% of sensitivity and 78.5% of speci-
ficities (Table 5). The anti-CCP assay showed better specificity
than other tests, and these results were consistent with those
of previous studies (2, 9, 13). Diagnostic accuracy among
anti-CCP, AFA, and RF assays by ROC curve was compared
and the area under the curve of the anti-CCP, AFA, and RF
were 0.837, 0.750, and 0.833, respectively. Diagnostic accu-
racy between the anti-CCP and RF was not significantly dif-
ferent (p=0.857), but that between AFA and RF was signif-
icantly different (p=0.000) (Fig. 1, 2).
DISCUSSION
The modern trend of RA treatment has been changed to
start treatment as early as possible, based on the concept that
early control of inflammation results in reduced joint damage
(14). The RF assay has known to have suboptimal sensitivity
and specificity for the diagnosis of RA. Therefore, easier, more
convenient, higher specific serological methods have been
required for the diagnosis of RA.
Recently, anti-CCP and AFA assays by ELISA method were
developed using the synthetic cyclic citrullinated peptide and
the recombinant anti-citrullinated filaggrin as substrates for
the diagnosis of RA, which was reported highly specific and
significant (2, 9). The native recombinant filaggrins do not
react with antifilaggrin autoantibodies, however, after in vitro
deimination, recombinant filaggrins become immunoreac-
tive (15). Schellekens et al. reported that synthetic peptides
were, in principle, ideal antigenic substrates and peptides
with a predefined sequence could be produced in large quan-
tities with a high degree of purity, and their relative small
size reduced the chance of nonspecific interactions occurring
with other serum components (2).
In this study, we evaluated the diagnostic performances of
anti-CCP and AFA assay by ELISA method as useful new
serological tests for the diagnosis of RA in 324 RA patients,
259 patients with other rheumatic disease and 286 healthy
subjects. In 286 healthy subjects, the number of anti-CCP,
AFA, RF positivity was 3 (1.0%), 73 (25.5%), 42 (14.7%)
at the optimal cut off values, respectively. Healthy subjects
with anti-CCP reactivity did not have any other rheumatic
disease and showed low titer of anti-CCP reactivity. We con-
sidered that the anti-CCP assay had higher specificity than
other assays in healthy population. In RA patients, sex ratio
(M:F) is 1:5.6 and the mean value of anti-CCP between male
and female had no significant difference in RA (p=0.761).
The diagnostic performance of anti-CCP and AFA in sera ob-
tained from patients with RA and other rheumatic disease
showed the sensitivity of 72.8%, 70.3% and the specificity
of 92.0%, 69.3% at the optimal cut off values, respectively.
Schellekens et al. reported that ELISA methods using the cyclic
citrullinated peptide (CCP-ELISA), in a series of 149 RA and
312 control sera, had a diagnostic sensitivity of 48% for a
specificity of 96% (2). Kroot et al. identified 66% positive
RA serum samples with CCP-ELISA (3). In this study, the
diagnostic sensitivity proposed for CCP-ELISA showed better
than that of other studies, and slightly lower specificity than
that of Schellekens et al. (2). However, we considered that our
study did not include healthy subjects in control group and
showed a slightly lower specificity of 92.0% compared to 96%
specificity by Schellekens et al. We concluded that anti-CCP
showed high specificity for the diagnosis of RA.
Nogueira et al. reported the diagnostic sensitivity of 52% for
a specificity of 95% with AFA-ELISA-rec (using the recom-
binant human filaggrin deiminated in vitro) and sensitivity
of 51% for a specificity of 95% with AKA (12). Palosuo et al.
developed ELISA methods for detection of the antifilaggrin
autoantibodies using purified human filaggrin and proposed
a sensitivity of 71% for a specificity of 95% (16). Aho et al.
reported 49% positive RA serum samples with their AhFA-
ELISA vs. 47% with APF (17). Vincent et al. reported that in
a series of 279 RA patients and 213 control patients, APF had
a sensitivity of 67% and a specificity of 93% and at 93% speci-
ficity, was better than AKA (57%) and AFA-immuno- blot-
ting (57%) (9). However, APF at 99% specificity was lower
sensitivity of 30% (9). In this study, the AFA assay was lower
specificity than other studies, however, it was as similar as the
sensitivity of APF. We considered that AFA might have lower
sensitivity, because AFA used a recombinant protein as target
antigens and its recombinant filaggrin corresponded to only one
filaggrin polypeptide of several filaggrin polypeptides (18).
The range of RF was 3-247 U/mL and the mean value of
RF had a significant difference between male and female inRA patients (p=0.001) (Table 2). We thought there was no
reported data about difference of mean value between male
and female in RA patients and we needed further evaluation.
The cut off value of RF was 9 U/mL and its sensitivity and
specificity was 80.6% and 78.5%. These results showed higher
sensitivity and lower specificity than those of Visser et al. using
the latex fixation test (sensitivity of 65.6%, specificity of 90.9%)
(13). Vittecoq et al. proposed that among ACR criteria, only
RF detected by agglutination tests was taken into account,
however, the measurement of IgM-RF by ELISA, in addition
to latex fixation test, could increase the number of RF-positive
cases in early RA (19). Visser et al. showed that the diagnostic
characteristics of the ELISAs for IgG and IgA RF in discrim-
inating RA from non-RA were poor and the test characteris-
tics of the ELISA for IgM RF and the latex fixation test proved
to be much better, and compared reasonably well to each other,
though the specificity of the latex fixation test was greater
than that of the ELISA for IgM (13). Schellekens et al. report-
ed the sensitivity of 54% and specificity of 91% by IgM-RF
ELISA (2). Visser et al. showed the sensitivity of 69.2% and
the specificity of 86.0% by IgM-RF ELISA, and suggested
that greater sensitivity and specificity of the latex fixation test
can be explained by differences in patient’s selection, criteria
for the diagnosis of RA, and study design (13).
Our study showed that the anti-CCP and AFA were highly
specific for RA and could be detected up to 23.8% and 17.3%
of RF-negative sera, respectively, compared to 35% of Sche-
llekens et al. (Table 3, 4) (2). The false positivity of anti-CCP
was 8.0% and following diseases were included; Behcet’s dis-
ease (n=1), fibromyalgia (n=1), gout (n=2), juvenile rheuma-
toid arthritis (n=6), osteoarthritis (n=6), reactive arthritis
(n=1), spondyloarthritis (n=2), and SLE (n=1) (Table 4). The
diagnostic accuracy among the anti-CCP, AFA, and RF was
compared, and the area under the curve of anti-CCP, AFA,
and RF was 0.837, 0.750, and 0.833, respectively. Diagnos-
tic accuracy between the anti-CCP and RF was not signifi-
cantly different (p=0.857), but that between AFA and RF was
significantly different (p=0.000) (Fig. 1, 2). Nogueira et al.
reported that the discrepancies between the performances of
the tests, which may result from the composition of the series
of patients analyzed and from subtle interlaboratory technical
differences in performing the same test, underline the difficul-
ties in comparing the results with each other objectively in
the absence of a common standardized reference test (12).
In conclusion, anti-CCP assay by ELISA could be performed
more objectively and quantitatively, and showed higher speci-
ficity than AFA and RF in patients with RA. Therefore, we
propose that anti-CCP assay could be a useful new serologi-
cal test for the diagnosis of Korean patients with RA.
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